 |
|
HLA Typing for Bone Marrow TransplantationNew Polymerase Chain Reaction—Based Methods
Ann B. Begovich, PhD;
Henry A. Erlich, PhD
JAMA. 1995;273(7):586-591.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
BONE MARROW transplantation, first introduced into clinical practice in the 1960s, has now become an accepted form of therapy for a variety of hematologic malignancies as well as a number of other cancers, inherited blood disorders, immunodeficiency syndromes, and certain metabolic diseases.1,2 In general, the purpose of bone marrow transplantation is to (1) replace malignant or genetically defective hematopoietic stem cells with healthy, fully functional stem cells; (2) allow the cancer patient to survive the high-dose radiation and/or chemotherapy required to destroy the malignant cells; and (3) in the case of certain cancers, provide a source of immunocompetent cells that can destroy any residual malignant cells (graft vs leukemia effect).3-5 The clinical procedure of bone marrow transplantation involves the destruction of the patient's own marrow by irradiation and/or chemotherapy followed by the infusion of healthy bone marrow obtained from another individual (an allogeneic transplant). In cases of solid
. . . [Full Text PDF of this Article]
Author Affiliations
From the Department of Human Genetics, Roche Molecular Systems Inc, Alameda, Calif. The PCR process is covered by issued and pending patents owned by Hoffmann-La Roche Inc and F. Hoffman-La Roche Ltd.
Footnotes
Reprint requests to Department of Human Genetics, Roche Molecular Systems Inc, 1145 Atlantic Ave, Alameda, CA 94501 (Dr Begovich).
Toward Optimal Laboratory Use section editor: George D. Lundberg, MD, Editor, JAMA.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
